CONCLUSIONS AND IMPLICATIONS
These results suggested that serelaxin alleviates cardiac fibrosis by inhibiting inflammatory products of IL-1β, IL-6 and TNF-α, α-SMA, collagen I/III in LPS-induced CFs by stimulating PPAR-γ which subsequently abolished the expression of NF-κB signalling pathways.
Key words: Serelaxin; PPAR-γ; NF-κB; LPS; Cardiac fibroblast; inflammation